UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 4, 2013
KEDEM PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Nevada
000-54455
98-0633727
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
8755 Ash Street, Suite 1
Vancouver, British Columbia, Canada V6P 6T3
(Address of principal executive offices) (Zip Code)
(604) 324-4844
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
--------------------------------------------------------------------------------
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 4, 2013, Kedem Pharmaceuticals Inc. (the “Company”) received the resignation of Audrey Lew as the Chief Financial Officer of the Company, effective immediately. Ms. Lew’s resignation did not result from any disagreement with the Company regarding its operations, policies, practices or otherwise. Concurrent with Ms. Lew’s resignation, Christian Bezy, a director of the Company, was appointed as its new Chief Financial Officer.
On January 7, 2013, the Company received the resignation of Dr. Hassan Salari as the President, Chief Executive Officer, Secretary, Treasurer and a director of the Company, effective immediately. Dr. Salari’s resignation did not result from any disagreement with the Company regarding its operations, policies, practices or otherwise.
As a result of Dr. Salari’s resignation, the Company’s Board of Directors and audit committee were each reduced from two members to one. The remaining director and audit committee member, Mr. Bezy, was concurrently appointed to replace Dr. Salari as the Company’s President, Chief Executive Officer, Secretary and Treasurer.
News 
Market Data 
Discover 
AI
